RT Journal Article
SR Electronic
T1 Safety and Potency of COVIran Barekat Inactivated Vaccine Candidate for SARS-CoV-2: A Preclinical Study
JF bioRxiv
FD Cold Spring Harbor Laboratory
SP 2021.06.10.447951
DO 10.1101/2021.06.10.447951
A1 Abdoli, Asghar
A1 Aalizadeh, Reza
A1 Aminianfar, Hossein
A1 Kianmehr, Zahra
A1 Azimi, Ebrahim
A1 Emamipour, Nabbi
A1 Jamshidi, Hamidreza
A1 Hosseinpour, Mohammadreza
A1 Taqavian, Mohammad
A1 Jalili, Hasan
YR 2021
UL http://biorxiv.org/content/early/2021/06/10/2021.06.10.447951.abstract
AB There is an urgent demand to manufacture an effective and safe vaccine to prevent SARS-CoV2 infection, which resulted in a global pandemic. In this study, we developed an inactivated whole-virus SARS-CoV-2 candidate vaccine named COVIran Barekat. Immunization at two different doses (3 µg or 5 µg per dose) elicited a high level of SARS-CoV-2 specific neutralizing antibodies in mice, rabbits, and non-human primates. The results show the safety profile in studied animals (include guinea pig, rabbit, mice, and monkeys). Rhesus macaques were immunized with the two-dose of 5 µg and 3 µg of the COVIran Barekat vaccine and showed highly efficient protection against 104 TCID50 of SARS-CoV-2 intratracheal challenge compared with the control group. These results highlight the COVIran Barekat vaccine as a potential candidate to induce a strong and potent immune response which may be a promising and feasible vaccine to protect against SARS-CoV2 infection.Competing Interest StatementThe authors have declared no competing interest.